CagriSema's FDA Decision Is Due Within Weeks: What Novo Nordisk Just Told Patients About the 2027 Launch

CagriSema is a once-weekly injection that combines two medicines in a single fixed dose: semaglutide 2.4 mg, the same GLP-1 found in Wegovy, and cagrilintide 2.4 mg, a long-acting analogue of amylin, a hormone that works alongside GLP-1 to regulate appetite and fullness. If approved, it would be the first combination of its kind.

The application rests largely on the REDEFINE 1 trial, a 68-week study of 3,417 adults with obesity, or overweight plus a weight-related health problem, who did not have diabetes. According to Novo Nordisk's filing announcement, participants on CagriSema lost 20.4% of their body weight on average, versus 3.0% with placebo — and 22.7% among those who stayed on treatment for the full trial. Nearly 92% of people on CagriSema lost at least 5% of their body weight, and roughly half of participants who started the trial with obesity finished it with a BMI below 30.

Those numbers put CagriSema at the top of the injectable class, in the same territory as the strongest results seen with tirzepatide — which is why we compared the two in detail earlier this year.

Three things stood out from the earnings call and the CEO's comments, as reported by Investing.com's coverage of the Q3 presentation:

The FDA decision is expected in Q4 2026. That is weeks away, not months. Doustdar said Novo is "hopeful that we will be able to get the timely approval from the FDA at the end of this year."

Launch is planned for early 2027 — through every channel. Novo says it will sell CagriSema through traditional pharmacies, its own NovoCare pharmacy, and e-health platforms from the start. That matters: when Wegovy launched in 2021, supply shortages and limited channels left patients waiting months. This time the company says manufacturing is already running ahead of approval.

Pricing was deliberately left blank. Doustdar declined to reveal a price, saying only that CagriSema would be priced "according to the value it provides." Until a list price and insurance coverage picture emerge, nobody can tell you what it will cost out of pocket.

CagriSema's safety profile looked broadly like other GLP-1 medicines in the trials, which means mostly gastrointestinal effects, concentrated in the first months as the dose increases. In REDEFINE 1, nausea affected 55% of participants, constipation about 31%, and vomiting about 26% — considerably more than placebo, though only 5.9% of people stopped treatment because of side effects.

That is a manageable picture for most patients, and the practical playbook is the same one used with semaglutide and tirzepatide today: slow dose escalation, dietary adjustments, and anti-nausea support when needed, like JoeyMed's anti-nausea add-on. As with any GLP-1 medication, CagriSema won't be right for everyone — people with a personal or family history of medullary thyroid cancer, a history of pancreatitis, or who are pregnant or planning pregnancy need a careful conversation first. Screening questions like these are exactly why these medicines are prescribed through a licensed provider rather than bought off a menu.

This is the question patients actually face, and the honest answer is that waiting has a cost. Even on Novo's best-case timeline, CagriSema is months from pharmacy shelves, its price is unknown, and insurance coverage typically lags a launch by months more. New medications also tend to launch at premium prices before competition and coverage catch up.

Meanwhile, the treatments available today are proven and increasingly accessible. Semaglutide and tirzepatide both produce substantial, sustained weight loss in their own right — tirzepatide's trial results are in the same conversation as CagriSema's — and options like Tirz HD exist now, at a known price, with provider support from day one. For most people with weight to lose and health risks accumulating, starting an effective treatment this month beats waiting half a year for one that may be only incrementally better, at a price nobody has seen.

If CagriSema is approved and turns out to fit you better, switching is a normal part of obesity care — your provider can manage that transition when the time comes, the same way patients moved between semaglutide and tirzepatide as each became available.

If you have been waiting on the sidelines for the "next" drug, the better move is usually a conversation about what works today. JoeyMed's licensed providers can review your health history, screen for contraindications, and build a weight loss treatment plan around medications that are available right now — with transparent pricing, ongoing check-ins, and side-effect support included. And when CagriSema arrives in 2027, we will cover exactly what its label, price, and coverage look like, so you and your provider can decide whether it earns a place in your plan.